Cargando…
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the r...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427952/ https://www.ncbi.nlm.nih.gov/pubmed/37593365 http://dx.doi.org/10.1159/000530134 |
_version_ | 1785090357916073984 |
---|---|
author | De, Brian Upadhyay, Rituraj Liao, Kaiping Kumala, Tiffany Shi, Christopher Dodoo, Grace Abi Jaoude, Joseph Corrigan, Kelsey L. Manzar, Gohar S. Marqueen, Kathryn E. Bernard, Vincent Lee, Sunyoung S. Raghav, Kanwal P.S. Vauthey, Jean-Nicolas Tzeng, Ching-Wei D. Tran Cao, Hop S. Lee, Grace Wo, Jennifer Y. Hong, Theodore S. Crane, Christopher H. Minsky, Bruce D. Smith, Grace L. Holliday, Emma B. Taniguchi, Cullen M. Koong, Albert C. Das, Prajnan Javle, Milind Ludmir, Ethan B. Koay, Eugene J. |
author_facet | De, Brian Upadhyay, Rituraj Liao, Kaiping Kumala, Tiffany Shi, Christopher Dodoo, Grace Abi Jaoude, Joseph Corrigan, Kelsey L. Manzar, Gohar S. Marqueen, Kathryn E. Bernard, Vincent Lee, Sunyoung S. Raghav, Kanwal P.S. Vauthey, Jean-Nicolas Tzeng, Ching-Wei D. Tran Cao, Hop S. Lee, Grace Wo, Jennifer Y. Hong, Theodore S. Crane, Christopher H. Minsky, Bruce D. Smith, Grace L. Holliday, Emma B. Taniguchi, Cullen M. Koong, Albert C. Das, Prajnan Javle, Milind Ludmir, Ethan B. Koay, Eugene J. |
author_sort | De, Brian |
collection | PubMed |
description | INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. METHODS: We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5–97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling. RESULTS: We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8–11) and 21 months (CI: 17–26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; p = 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; p = 0.005) and receipt of L-RT (HR: 0.40; p = 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; p < 0.001). CONCLUSION: For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted. |
format | Online Article Text |
id | pubmed-10427952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-104279522023-08-17 Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases De, Brian Upadhyay, Rituraj Liao, Kaiping Kumala, Tiffany Shi, Christopher Dodoo, Grace Abi Jaoude, Joseph Corrigan, Kelsey L. Manzar, Gohar S. Marqueen, Kathryn E. Bernard, Vincent Lee, Sunyoung S. Raghav, Kanwal P.S. Vauthey, Jean-Nicolas Tzeng, Ching-Wei D. Tran Cao, Hop S. Lee, Grace Wo, Jennifer Y. Hong, Theodore S. Crane, Christopher H. Minsky, Bruce D. Smith, Grace L. Holliday, Emma B. Taniguchi, Cullen M. Koong, Albert C. Das, Prajnan Javle, Milind Ludmir, Ethan B. Koay, Eugene J. Liver Cancer Research Article INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. METHODS: We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5–97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling. RESULTS: We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8–11) and 21 months (CI: 17–26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; p = 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; p = 0.005) and receipt of L-RT (HR: 0.40; p = 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; p < 0.001). CONCLUSION: For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted. S. Karger AG 2023-03-16 /pmc/articles/PMC10427952/ /pubmed/37593365 http://dx.doi.org/10.1159/000530134 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Research Article De, Brian Upadhyay, Rituraj Liao, Kaiping Kumala, Tiffany Shi, Christopher Dodoo, Grace Abi Jaoude, Joseph Corrigan, Kelsey L. Manzar, Gohar S. Marqueen, Kathryn E. Bernard, Vincent Lee, Sunyoung S. Raghav, Kanwal P.S. Vauthey, Jean-Nicolas Tzeng, Ching-Wei D. Tran Cao, Hop S. Lee, Grace Wo, Jennifer Y. Hong, Theodore S. Crane, Christopher H. Minsky, Bruce D. Smith, Grace L. Holliday, Emma B. Taniguchi, Cullen M. Koong, Albert C. Das, Prajnan Javle, Milind Ludmir, Ethan B. Koay, Eugene J. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title | Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title_full | Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title_fullStr | Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title_full_unstemmed | Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title_short | Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases |
title_sort | definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427952/ https://www.ncbi.nlm.nih.gov/pubmed/37593365 http://dx.doi.org/10.1159/000530134 |
work_keys_str_mv | AT debrian definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT upadhyayrituraj definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT liaokaiping definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT kumalatiffany definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT shichristopher definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT dodoograce definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT abijaoudejoseph definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT corrigankelseyl definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT manzargohars definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT marqueenkathryne definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT bernardvincent definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT leesunyoungs definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT raghavkanwalps definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT vautheyjeannicolas definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT tzengchingweid definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT trancaohops definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT leegrace definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT wojennifery definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT hongtheodores definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT cranechristopherh definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT minskybruced definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT smithgracel definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT hollidayemmab definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT taniguchicullenm definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT koongalbertc definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT dasprajnan definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT javlemilind definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT ludmirethanb definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases AT koayeugenej definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases |